ZeNix trial results show effectiveness of regimen against highly drug-resistant TB

The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.

To read the full announcement of TB Alliance, click here.

For more updates from TB Alliance, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By TB Alliance

Published: July 15, 2021, 9 a.m.

Last updated: July 16, 2021, 8:37 a.m.

Print Share